Custom Search

News

Tuesday 01 June 2004

Intraventricular treatment of relapsed central nervous system lymphoma with the anti-CD20 antibody rituximab.

By: Schulz H, Pels H, Schmidt-Wolf I, Zeelen U, Germing U, Engert A.

Haematologica 2004 Jun;89(6):753-4

Most patients with primary central nervous system (CNS) lymphoma or systemic non-Hodgkin's lymphoma (NHL) involving the CNS relapse after an initial response to treatment, often presenting with leptomeningeal disease. Since the majority of these lymphomas are B-cell neoplasms expressing the CD20 surface antigen treatment with the chimeric monoclonal antibody (Mab) rituximab might be a new therapeutic option. Here, we report on 6 patients with relapsed CNS B-cell lymphoma who were treated with intraventricular or intrathecal applications of rituximab. One of these cases has already been reported.

Use of this site is subject to the following terms of use